EGFR and neuroblastoma: Similarly, we also showed that the NSCLC model acquired hyperactivation of EGFR after exposure to lorlatinib (i.e., H3122-LR100 cell line), whereas the lorlatinib-resistant neuroblastoma cell line GLB-Ga-LR1000 was associated with the hyperactivation of EGFR and ErbB4 [30].